For customers seeking to ensure the safety and efficacy of their CRISPR-based therapeutic developments through off-target analysis, our comprehensive end-to-end services encompass assays from off-target nomination to confirmation, with outputs specifically tailored for IND filings.
We've been long-time users of IDT DNA oligos in all their variants. Recently, we ventured into CRISPR technology and came to rely on IDT sgRNAs for their dependable performance and super-fast delivery. The combination of high quality, improved stability, and quick turnaround helps keep our gene editing projects moving forward without delays. Even after several freeze-thaw cycles, IDT sgRNAs remain stable and continue to perform reliably.
Edyta Szewczyk
UC Berkeley
| Key Specifications |
Cas9 System
 |
Cas12a System
 |
|---|---|---|
| Applications | General Genome Editing |
|
| Ribonucleoprotein components |
|
|
| Variants |
|
|
| Cas9 crRNA:tracrRNA (option 1) |
crRNA
tracrRNA
|
__ |
| Cas9 sgRNA (option 2) |
|
__ |
| Cas12a crRNA | __ |
|
| CRISPR enzyme |
|
|
| DNA cleavage |
|
|
| PAM sequence† |
|
|
| Current recommendations for Alt-R RNP delivery |
|
|
IDT does not sell gene therapy kits, and nothing sold by IDT should be construed as a gene therapy kit. Customers should not use any IDT products for self-administration.
CGMP gRNA products are manufactured in accordance with ICH Q7, 21CFR210, 211, and parts of 600. IDT engineering runs and CGMP gRNA are for development and investigational use only. The performance characteristics of this product have not been established. This product is not intended to be used as final drug product. The purchaser is solely responsible for all decisions regarding the intended use of the product and any associated legal or regulatory obligations.
RUO24-3155_001
